Header for print stylesheet
You are here:  
DSM announces that RONOZYME® ProAct is now available in the European Union
Kaiseraugst,CH,07 Apr 2010

RONOZYME® ProAct, the first pure protease for the poultry industry, has received regulatory approval in the European Union. This innovative feed enzyme has been successfully marketed in Brazil and Turkey, followed by launches in Latin America and Asia Pacific. It is now available in EU-27 for the first time and it will be launched on April 20th, during VIV Europe.

The new feed enzyme offers the poultry industry many advantages. Dependent on feed protein source, it reduces feed costs on average by 5% by maximizing protein utilization and improving nutritional value while simultaneously enhancing animal performance up to 6%. RONOZYME® ProAct is a mono component protease that unlocks the nutritional value of a large variety of feed proteins by complementing the activity of digestive enzymes such as pepsin and pancreatic proteases. At the same time, it reduces the levels of nitrogen excreted by broilers, therefore diminishing the environmental impact of the poultry industry.

“RONOZYME® ProAct is the innovative feed enzyme that every broiler needs to maximize the protein of the diet provided to the animal,” comments Jean-Paul Ruckebusch, Alliance manager at DSM Nutritional Products. “Obtaining product approval for RONOZYME® ProAct in Europe is part of a wider strategy to make this breakthrough product available to the broiler industry worldwide.”

The RONOZYME® product range of feed enzymes is developed within the Alliance of DSM Nutritional Products and Novozymes and represents the most complete feed enzyme portfolio within the feed industry. RONOZYME® ProAct is the newest feed enzyme in the great range of RONOZYME® enzymes.

RONOZYME® ProAct is fully compatible with phytases and other feed enzymes commonly used in broiler feed. The global registration process continues.

About DSM Nutritional Products
DSM Nutritional Products is the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. The business has sales of over EUR 2 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. More information at www.dsmnutritionalproducts.com and www.qualityforlife.com

DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and MaterialsSciences that contribute to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of about € 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

About Novozymes
Novozymes is the world leader in bio innovation. Together with customers across a broad array of industries, the company creates tomorrow’s industrial bio solutions, improving its customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bio innovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever changing marketplace. Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food, to advancing bio fuels to power the world tomorrow. Its never-ending exploration of nature’s potential is evidenced by over 4,500 patents, showing what is possible when nature and technology join forces. More than 4,500 employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow. Novozymes is quoted on NASDAQ OMX Copenhagen (NZYMB). Read more at www.novozymes.com

For more information:
DSM Nutritional Products
Emma Peyrachon
Tel: +41 (0)61 815 83 54
Fax: +41 (0)61 815 88 90
E-mail: emma.peyrachon@dsm.com

PDF version (24 Kb)

Pdf document
For more information:
DSM Nutritional Products, Emma Peyrachon
Tel: +41 (0)61 815 83 54
emma.peyrachon@dsm.com
footer for print stylesheet